

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : <b>A01N 25/00</b>	A1	(11) International Publication Number: <b>WO 99/63816</b> (43) International Publication Date: 16 December 1999 (16.12.99)
(21) International Application Number: PCT/US99/13048		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 9 June 1999 (09.06.99)		
(30) Priority Data: 60/088,560 9 June 1998 (09.06.98) US		
(71)(72) Applicant and Inventor: EMBRO, William, J. [US/US]; 832 Northwest 57th Street, Gainsville, FL 32605 (US).		
(74) Agent: HANSON, Norman; Fulbright & Jaworski LLP, 666 Fifth Avenue, New York, NY 10103 (US).		

**Published***With international search report.**Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.***(54) Title:** METHOD AND COMPOSITION FOR THE TREATMENT OF EPIDERMAL IRRITATIONS AND INFECTIONS**(57) Abstract**

An improved stannous fluoride composition is disclosed. The composition comprises stannous fluoride and at least one zinc containing compound. The zinc containing compounds stabilized and prevent hydrolysis of the stannous ions resulting in a more effective stannous fluoride composition for use in the treatment of epidermal irritations and infections.

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

**Title:** Method and Composition for the Treatment  
of Epidermal Irritations and Infections

**FIELD OF THE INVENTION**

The present invention relates to an improved stannous  
5 fluoride composition for the treatment of epidermal irritations and  
infections.

**BACKGROUND OF THE INVENTION**

Stannous fluoride has been used in dentistry since the 1950's  
to prevent dental cavities. Norman Tinanoff outlines 40 years of human  
10 and animal studies with some studies having greater efficacy than others  
in "Review of the Antimicrobial Action of Stannous Fluoride" (The  
Journal of Clinical Dentistry Vol. II 1990). United states patent 4,097,590  
"Methods and Compositions for Treatment of Bacteria and Fungus  
infections of the skin" discloses treatment for vulgaris and athletes foot  
15 with a soluble fluoride salt. The present inventor previously determined  
that stannous fluoride can be used for treating diseases having viral  
etiology. (US. Patent No. 5,098,716 to Embro).

Both the shelf life and antimicrobial effect of a stannous  
fluoride product depend on stability of the active stannous ion ( $\text{Sn}^{+2}$ ).  
20 Products formulated for home use achieve stability of the stannous ion by  
adding glycerin or other water-insoluble materials to reduce hydrolysis  
and oxidation. Aqueous formulations employed chelating agents which  
bind stannous fluoride and create a stannous reservoir that acts both as a  
supply of stannous ions and an antioxidant. Majeti et. al. (U.S. Patent No.  
25 5,004,597), developed a dentifrice stabilization system for stannous fluoride  
by utilizing stannous chloride as an antioxidant with stannous reservoir  
and sodium gluconate as a chelating agent to protect stannous fluoride  
from hydrolysis. Other chemicals used in stannous fluoride stabilization  
30 include polyvinyl alcohol (PVA), tripolyphosphates, copolymers of  
vinyl-methylether and maleic anhydride. However, the use of these and  
other complexing agents for stannous fluoride stabilization can limit the  
bioavailability of stannous ions for a therapeutic effect.

- 2 -

In view of the foregoing, there is a need to provide improved stannous fluoride compositions.

#### SUMMARY OF THE INVENTION

The present invention relates to an improved stannous fluoride composition comprising stannous fluoride and at least one zinc containing compound. The inventor has shown that the improved composition is more stable and less toxic than a stannous fluoride composition that does not contain a zinc compound. The inventor has also shown that the improved composition of the invention allows one to decrease the dose of stannous fluoride required to achieve a therapeutic effect.

The inventor has demonstrated that the improved composition of the invention is effective in treating epidermal irritations and infections and their symptoms. Accordingly, the present invention also provides a method of treating an epidermal irritation or infection comprising administering an effective amount of a composition comprising stannous fluoride and at least one zinc containing compound to an animal in need thereof.

Other features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples while indicating preferred embodiments of the invention are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

#### DETAILED DESCRIPTION OF THE INVENTION

##### COMPOSITIONS OF THE INVENTION

The present invention relates to an improved stannous fluoride composition comprising stannous fluoride and at least one zinc containing compound. This composition may be referred to herein as "the composition of the invention".

- 3 -

The composition of the invention is markedly improved over a composition containing stannous fluoride without any zinc compounds in several respects. Firstly, stannous fluoride undergoes hydrolysis and oxidation in aqueous environments which results in the 5 loss of stannous bioavailability due to the precipitation of stannous hydroxide. The zinc containing compounds stabilize the stannous fluoride by preventing the oxidation and hydrolysis of the stannous ion. Zinc ions have a greater affinity than stannous ions for hydroxides and other anions in aqueous solutions. As a result the zinc in the composition 10 of the invention will complex the hydroxides and inhibit hydrolysis and precipitation of the stannous ions. In particular, the inventor has demonstrated that a stannous fluoride solution containing zinc gluconate remained stable, without precipitation, for at least 3 months. In contrast, a stannous fluoride solution without zinc gluconate extensively 15 precipitated. Secondly, the zinc compounds buffer the hydrogen ion which promotes an elevated pH. This makes the composition more suitable for topical use as more acidic formulations can irritate or cause a burning sensation of the skin. Thirdly, the present inventor has unexpectedly found that the zinc compounds act synergistically with and 20 potentiate the activity of the stannous fluoride. In particular, the present inventor has demonstrated that in the composition of the invention the stannous fluoride works better than when twice the dose is used in a composition that does not contain the zinc compounds. Consequently, the dose of the stannous fluoride can be significantly lowered in the 25 composition of the invention resulting in a less toxic composition.

As mentioned above, inclusion of zinc compounds in the composition of the present invention stabilizes and enhances the efficacy of the stannous fluoride. Using zinc containing compounds in the composition also has additional advantages in that zinc is widely 30 recognized as having medicinal and healing properties. In particular, 1) zinc is essential for life; 2) zinc is necessary for over 100 enzymes (i.e., alcohol dehydrogenase carboxypeptidase); 3) zinc maintains body levels of

- 4 -

Vitamin A; 4) zinc is important in sex organ function and reproduction; 5) zinc is important for DNA/RNA synthesis; 6) zinc can improve cell-mediated immunity; and 7) zinc is incorporated in hundreds of dermatological formulas to help maintain healthy skin cells. Using  
5 stannous compounds with the stannous fluoride will not provide the added benefits that zinc does as stannous is not essential for life and is not necessary for enzyme function.

The zinc containing compound can be any compound containing zinc including zinc carboxylates and zinc salts. The zinc  
10 carboxylate is preferably selected from one or more of zinc gluconate, zinc tartrate, zinc malate, zinc propionate, zinc citrate and zinc acetate. More preferably, the zinc carboxylate is zinc gluconate. The zinc salt is preferably selected from zinc chloride, zinc sulfate, zinc phosphate, zinc pyrophosphate, zinc oxide or zinc thiocyanate. Preferably, the zinc salt is  
15 zinc chloride.

The composition of the invention preferably comprises stannous fluoride in a concentration ranging from about .01 wt % to about 10.0 wt % and one or more zinc containing compound in an amount from about 0.05 wt % to about 20.0 wt %.

In a preferred embodiment, the composition comprises stannous fluoride and zinc gluconate. The inventor has shown that a composition comprising stannous fluoride and zinc gluconate provides significantly greater efficacy in the treatment of a viral, bacterial and fungal infections as compared to a stannous fluoride composition alone. In  
20 particular, the inventor has demonstrated that with the improved composition one can use one half the amount of stannous fluoride as is used in a composition containing stannous fluoride alone with improved results.

Preferably, the stannous fluoride is provided in a  
30 concentration ranging from about 0.1 wt. % to about 8.0 wt. % and zinc gluconate is provided in concentration ranging from about 0.5 wt. % to about 10.0 wt. %. Most preferably, the composition comprises 0.20 %

- 5 -

stannous fluoride and 1.5% zinc gluconate, in a non-aqueous medium such as glycerin.

The composition may additionally contain zinc chloride in a concentration ranging from about 0.5 wt. % to about 5.0 wt. %. The addition of zinc chloride may be useful in compositions with a high aqueous content (i.e. >80% water).

The composition of the invention can include more than one zinc containing compound. For example, the zinc compound may be zinc gluconate, zinc chloride and/or zinc acetate.

10 The composition may additionally include one of the essential or non-essential  $\alpha$ , L or D amino acids selected from the group consisting of lysine, arginine, histidine, phenylalanine, threonine, leucine, isoluceine, cysteine, methionine, valine, alanine, glycine, proline, glutamine, serine, tryptophan, tyrosine and asparagine.

15 The composition can be formulated using techniques known in the art for example as described in Remington's Pharmaceutical Sciences, Eighteenth Edition, Mack Publishing Company. The composition is preferably a gel, ointment, cream, lotion, spray or the like, suitable for topical administration. Advantageously, the composition of 20 the present invention maintains its bioavailability at a pH suitable for topical administration. The composition may also include pharmaceutically acceptable diluents or carriers including water, carbopol, glycerin and hydroxymethyl cellulose.

25 The composition of the invention may additionally include excipients known in the art including fillers such as saccharides, for example, lactose or sucrose, mannitol or sorbitol cellulose preparations and/or calcium phosphates, for example, tricalcium phosphate or calcium hydrogen phosphate, as well as binders such as starch paste, using for example, maize starch, wheat starch, rice starch, potato starch, gelatin, 30 tragacanth, methyl cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and/or polyvinyl pyrrolidone. In some cases, it

- 6 -

may be desirable to add disintegrating agents such as the above mentioned starches and also carboxymethyl-starch, cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate. Auxiliaries are, above all, flow-regulating agents and lubricants, for 5 example, silica, talc, steric acid or salts thereof, such as magnesium stearate or calcium stearate, and/or polyethylene glycol.

The compositions of the invention may contain, as additives, preservatives such as p-hydrobenzoates (nipa esters, methylparaben), sorbic acid, chlorhexidine digluconate, benzalkonium chloride and 10 hexadecyltrimethyl ammonium bromide.

In order to accelerate the absorption of the composition through the skin, permeation accelerators such as dimethylsulfoxide or tauroglycolic acid may be added to the composition.

Hydrogel forming agents which may be used include gelatine 15 and cellulose derivatives such as methylcellulose, hydroxypropylcellulose and hydroxyethylcellose, as well as synthetic polymers such as polyvinyl alcohol. The nature and quantity of the hydrogel forming agents used or the mixtures thereof will depend on the particular viscosity required.

20 The additives which may be present also include moisture-retaining substances such as glycerol, sorbitol, 1,2-propyleneglycol, butyleneglycol and polyols.

#### **USES OF THE COMPOSITIONS**

The inventor has demonstrated that the improved 25 composition of the invention is effective in treating epidermal irritations and infections and their symptoms. Accordingly, the present invention also provides a method of treating an epidermal irritation or infection comprising administering an effective amount of a composition comprising stannous fluoride and at least one zinc containing compound 30 to an animal in need thereof. The zinc containing compound is preferably zinc gluconate and may optionally include zinc chloride.

- 7 -

The term "effective amount" means providing an amount at dosages and for periods of time that is effective to achieve the desired result. The frequency of application of the composition of the invention may range anywhere from one to six times a day, or as needed for the  
5 healing process. The course of the therapy typically ranges from one to six times a day, for several days, and may be continued as long as required for complete relief.

The term "animal" as used herein includes all members of the animal kingdom. Preferably, the animal is a mammal such as a  
10 human, horse, dog or cat.

The term "epidermal irritation" means any condition that adversely affects or irritates the skin or coat of an animal including, but not limited to, insect bites, fleas, burns, psoriasis, dermatitis, acne and epidermal infections such as subcutaneous mycoses (sporotrichosis,  
15 phycomycosis, phacohypomycosis); Cutaneous Habronemiasis; Cutaneous Onchocerciasis (*Onchocerca cervicalis*); Seborrhea; Dermatophilosis (*Dermatophilus congolensis*); Dermatophytosis (*Trichophyton equinum*, *Trichophyton mentagrophytes*, *Trichophyton verrucosum*); Warble fly larvae (*Hypoderma spp*); or Bot fly larvae (*Gasterophilus*  
20 *nasalis*/*Gasterophilus hemorradalis*).

The term "infection" means any infection including, but not limited to, viral, bacterial, fungal and parasitic infections, that affects animals.

The viral infections that may be treated using the  
25 composition of the invention include herpes viruses such as Herpes Simplex I which causes cold sores and Herpes Zoster which causes shingles; Epstein-Barr virus; Papilloma virus which causes warts; cytomegalovirus; hepatitis virus; varicella-zoster virus which causes chicken pox; cold and flu viruses; human and feline leukemia viruses;  
30 human immunodeficiency viruses (HIVs) and viruses that cause ringworm.

- 8 -

The bacterial infections that may be treated using the composition of the invention include Streptococcus, Staphlococcus and Dermatophilus skin infections as well as mycoplasmas related to chronic sinus infections.

5       The fungal infections that may be treated using the composition of the invention include yeast infections of the oral cavity and vagina; fungal infections of the fingernails and feed (athletes foot); and fungal infections of the horse and cow epidermis including infections caused by the genera Microsporum and Trichophyton.

10      The composition of the invention is particularly well suited for the treatment of epidermal infections such as infections of the skin as well as ocular or eye infections. The inventor has shown that the composition is effective in treating many infections in human patients as well as in other mammals including horses, cats and dogs.

15      The present invention also provides a use of a composition comprising stannous fluoride and at least one zinc containing compound to treat an epidermal irritation or infection. The invention further provides a use of a composition comprising stannous fluoride and at least one zinc containing compound to prepare a medicament to treat an  
20     epidermal irritation or infection.

The following non-limiting examples are illustrative of the present invention:

#### EXAMPLES

##### Example 1

25      A composition of the present invention comprising stannous fluoride (0.2%) and zinc gluconate (1.5%) was compared to a composition containing stannous fluoride (0.4%) on the ability to treat cold sores caused by herpes virus. A placebo containing glycerin only was also prepared. Each composition was tested on 10 patients. The results, shown in Table 1,  
30     demonstrate that the average healing time for the group receiving stannous fluoride with zinc gluconate was 4.2 days as compared to 5.9 days for the group receiving stannous fluoride alone. This is a significant

- 9 -

reduction in healing time. In addition, the composition containing zinc gluconate contained one half the amount of stannous fluoride as compared to the stannous fluoride alone composition. Consequently, the composition of the present invention provides a much more efficacious  
5 composition as evidenced by the reduced healing time and reduced amount of stannous fluoride required.

**Example 2**

Five horses infected by the bacterium, *Dermatophilus congolensis* (commonly known as rain scald) were cured when several  
10 applications of a 0.2% stannous fluoride/1.5% zinc gluconate gel was applied over a period of two weeks.

**Example 3**

Five horses infected by fungi of the genera *Microsporum* and *Trichophyton* received immediate relief and were cured of the infection in  
15 a one week period when treated with a 0.2% stannous fluoride/1.5% zinc gluconate gel.

**Example 4**

Five colts suffering from warts (papilloma virus) on the muzzle, were successfully cured of the disease by applying a 0.2% stannous  
20 fluoride/1.5% zinc gluconate gel to the affected area several times a day for two weeks. There was no scarring.

**Example 5**

Several equines were successfully treated for pastern dermatitis (grease heel, scratches, mud fever) the cause of a  
25 staphylococcus/streptococcus/ *Dermatophilus* infection with topical and bandaged applications of a 0.2% stannous fluoride/1.5% zinc gluconate gel.

**Example 6**

Several cats were treated to control ringworm and oral facial sores of viral etiology with a 0.2% stannous fluoride/1.5 % zinc gluconate  
30 gel.

- 10 -

**Example 7**

Several dogs with bacterial skin infections the result of intense scratching due to insect bites were successfully treated with several applications of a 0.2% stannous fluoride/1.5% zinc gluconate gel.

5   **Example 8**

A patient, burned with candle wax flame resulting in a six inch diameter burn area, used two applications of a 0.2% stannous fluoride/1.5% zinc gluconate gel daily. As a result, the patient did not require the use of pain medication and antibiotics for infection. The 10 composition not only relieved severe pain but also prevented blistering and infection. The area was totally healed in less than three weeks with minimal scarring.

**Example 9**

15 A patient burned on an electric heating coil of a stove did not blister after an immediate application of a 0.2% stannous fluoride/1.5% zinc gluconate gel. The patient did not scab and the area did not get infected.

**Example 10**

20 Other skin ailments successfully treated with several applications of a 0.2% stannous fluoride/1.5% zinc gluconate gel, include acne, infected bug bites, warts, ringworm, and psoriasis. It appears that the antimicrobial effect of stannous fluoride and the immune stimulatory properties of zinc gluconate synergistically enhance healing due to microbial infections.

25   **Example 11**

**Treatment of Herpes**

30 A composition of the present invention comprising 0.2% stannous fluoride; 0.2% zinc chloride and 1.5% zinc gluconate and the remainder glycerin was compared to a 0.4% stannous fluoride in glycerin composition in the treatment of herpes simplex virus I (cold sores). The study consisted of two groups of 10 healthy adults with cold sores. One group was treated with the composition containing the zinc compounds

- 11 -

and the second group with the stannous fluoride alone composition. The adults treated with the composition containing the zinc compounds had a mean healing time of 3.1 days while the group treated with the stannous fluoride alone had a mean healing time of 3.9 days. As a result, the group  
5 treated with the composition of the invention that contained one half the amount of stannous fluoride as the other composition, healed at a faster rate. This study illustrates that the composition of the invention treats herpes infections with much greater efficacy than a composition containing stannous fluoride alone.

10 **Example 12**

**Treatment of Shingles**

The composition of Example 11 was used to treat several patients having a shingles outbreak. The patients reported a relief of pain and fast healing when treated with the composition of the invention. In  
15 addition, when compared with a composition containing stannous fluoride alone, the patients reported less burning with the composition of the invention.

**Example 13**

**Treatment of Bacterial Infections**

20 One patient was treated with the composition of Example 11 for impetigo which is a streptococcus infection of the skin. The treatment was successful. Another patient used a gel formulation of the present invention to control a resistant staphococcus skin infection.

**Example 14**

25 **Treatment of Cold and Flu**

The composition of Example 11 was used to successfully treat sore throats associated with colds and flu.

**Example 15**

**Treatment of Mycoplasma Infection**

30 The composition of Example 11 was used to successfully treat mycoplasmas related to a chronic sinus infection.

- 12 -

**Example 16**

**Treatment of Fungal Infections**

Fungal infections associated with human fingernails and feet (athlete's foot), and horse and cow epidermis as well as fungal infections of  
5 the oral cavity and vagina were successfully treated with the composition of Example 11.

**Example 17**

**Treatment of Cat Oral Ulcers**

Cat oral ulcers of viral and rickettsial origin resulted in fast  
10 healing when the composition of Example 11 was applied several times.

**Example 18**

**Treatment of Horses**

The composition of Example 11 has been used to treat many show horses for ringworm, papilloma virus, warts on the nose and  
15 parasitic irritations including mites and fly bites. All treatments were successful.

**Example 19**

**Treatment of Bovines**

The composition of Example 11 has been used to treat bovine  
20 skin conditions.

**Example 20**

**Preparation of the Compositions of the Invention**

To prepare the compositions of the invention all pharmaceutical mediums are heated to 150°F and percolated with nitrogen  
25 gas to displace oxygen and eliminate water so that the stannous ion is free from oxidation and hydrolysis during the mixing process of stannous fluoride with zinc compounds. Suitable pharmaceutically accepted vehicles may be used separately or in combination include glycerin, water, ethanol, polyethylene glycol, polypropylene glycol, and the like. The  
30 following provides specific formulations that are within the scope of the present invention.

- 13 -

<u>Component</u>	<u>Percent by weight</u>
Stannous fluoride	0.20
Zinc gluconate	1.50
Glycerin	98.30

<u>Component</u>	<u>Percent by weight</u>
Stannous fluoride	0.20
Zinc gluconate	2.50
Zinc chloride	0.50
Glycerin	96.80

<u>Component</u>	<u>Percent by weight</u>
Stannous fluoride	0.20
Zinc acetate	2.50
Zinc chloride	0.50
Glycerin	96.80

<u>Component</u>	<u>Percent by weight</u>
Stannous fluoride	0.20
Zinc gluconate	2.80
Zinc chloride	0.50
L-Lysine	15.50
Glycerin	75.00
Carbopol	6.00

<u>Component</u>	<u>Percent by weight</u>
Stannous fluoride	0.25
Zinc gluconate	1.50
Zinc chloride	0.50
Glycerin	92.50
Carbopol	3.00

- 14 -

<u>Component</u>	<u>Percent by weight</u>
Stannous fluoride	0.20
Zinc propionate	2.50
Zinc chloride	0.50
5 Glycerin	96.80

<u>Component</u>	<u>Percent by weight</u>
Stannous fluoride	0.20
Zinc propionate	2.50
10 Zinc chloride	0.50
Glycerin	97.30

<u>Component</u>	<u>Percent by weight</u>
Stannous fluoride	0.25
15 Zinc gluconate	2.25
Zinc chloride	0.50
Hydroxymethyl cellulose	30.25
Glycerin	65.50
Carbopol	3.25

While the present invention has been described with reference to what are presently considered to be the preferred examples, it is to be understood that the invention is not limited to the disclosed examples. To the contrary, the invention is intended to cover various 25 modifications and equivalent arrangements included within the spirit and scope of the appended claims.

All publications, patents and patent applications are herein incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and 30 individually indicated to be incorporated by reference in its entirety.

- 15 -

TABLE 1

Healing Time (days)		
SnF2+ZnGlu	SnF2	Placebo
5	6	7
8	9	11
4	5	6
3	4	4
4	8	7
5	6	8
3	4	9
2	4	6
3	6	10
5	7	4
Mean =	4.2	5.9
		7.2

**I CLAIM:**

1. A composition comprising stannous fluoride and at least one zinc containing compound.
2. A composition according to claim 1 wherein the zinc containing compound is a zinc carboxylate.
3. A composition according to claim 2 wherein the zinc carboxylate is selected from the group consisting of zinc gluconate, zinc tartrate, zinc malate, zinc citrate and zinc acetate.  
10
4. A composition according to claim 2 wherein the zinc carboxylate is zinc gluconate.
5. A composition according to claim 2 wherein the zinc containing compound further includes a zinc salt.  
20
6. A composition according to claim 5 wherein the zinc salt is selected from the group consisting of zinc chloride, zinc sulfate, zinc phosphate, zinc oxide, zinc pyrophosphate and zinc thiocyanate.
7. A composition according to claim 5 wherein the zinc salt is zinc chloride.  
20
8. A composition according to claim 1 comprising stannous fluoride and zinc gluconate in a non-aqueous medium.
9. A composition according to claim 1 further comprising at  
30 least one amino acid.

- 17 -

10. A composition according to claim 9 wherein the amino acid  
is an essential or non-essential L or D amino acids from the group  
consisting of lysine, arginine, histidine, phenylalanine, threonine,  
leucine, isoluceine, cysteine, methionine, valine, alanine, glycine, proline,  
5 glutamine, serine, tryptophan, tyrosine, and asparagine.
11. A composition according to claim 1 wherein the stannous  
fluoride is in an amount from about 0.01 % to about 10.0 % by weight.
- 10 12. A composition according to claim 2 wherein the zinc  
carboxylate is in an amount from about 0.05 % to about 10.0 % by weight.
13. A composition according to claim 5 wherein zinc salt is in an  
amount from about 0.05 % to about 10.0 % by weight.
14. A composition according to claim 9 wherein the amino acid  
is in an amount of from about 0.05 % to about 50.0 % by weight.
15. A composition according to claim 9 wherein the amino acid  
20 is L-Lysine.
16. A composition according to claim 1 comprising:
- |    |                   |                   |
|----|-------------------|-------------------|
| 25 | Stannous fluoride | 0.20 % by wt;     |
|    | Zinc gluconate    | 1.50 % by wt; and |
|    | Glycerin          | 98.30 % by wt.    |

- 18 -

17. A composition according to claim 5 comprising:

	Stannous fluoride	0.20 % by wt;
	Zinc gluconate	1.50 % by wt;
5	Zinc chloride	0.50 % by wt;
	Glycerin	85.50 % by wt; and
	Carbopol	7.30 % by wt.

18. A composition according to claim 5 comprising:

	Stannous fluoride	0.20 % by wt;
	Zinc gluconate	1.50 % by wt;
	Zinc chloride	0.50 % by wt;
	L-Lysine	10.00 % by wt;
15	Glycerine	60.00 % by wt;
	Carbopol	2.00 % by wt; and
	Distilled Water	24.80 % by wt.

19. A method of treating an epidermal irritation or infection  
20 comprising administering an effective amount of a composition  
comprising stannous fluoride and at least one zinc containing compound  
to an animal in need thereof.

20. A method according to claim 19 wherein the infection is a  
25 viral, bacterial, parasitic or fungal infection.

21. A method according to claim 20 wherein the viral infection is  
a herpes infection.

30 22. A method according to claim 20 wherein the viral infection is  
papilloma virus.

- 19 -

23. A method according to claim 20 wherein the fungal infection is caused by the genera Microsporum or Trichophyton.

24. A method according to claim 20 wherein the bacterial infection is caused by Staphylococcus bacterial, Streptococcus or Dermatophilis.  
5

25. A method according to claim 19 wherein the epidermal irritation is a burn.

26. A method according to claim 20 wherein the animal is a human.

27. A method according to claim 20 wherein the animal is a  
15 horse, cat or dog.

## INTERNATIONAL SEARCH REPORT

International application No. PCT/US99/13048
---

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A01N 25/00

US CL : 424/405

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/405

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X - Y	US 5,672,351 A (CHIKINDAS et al) 30 September 1997, col. 3, lines 2, 12-19 and 29-37 and 51-53, col. 4, line 50, col. 5, lines 9-23, col. 3, lines 2, 12-19 and 29-37 and 51-53, col. 4, line 50, col. 5, lines 9-23.	1-3, 5-7, 9-16, 19-20, 24, 26-27 ---- 4, 8, 17-18, 21-23, 25
X - Y	US 5,416,075 A (CARSON et al) 16 May 1995, abstract, col. 1, lines 40, 47, 49, 55-56, col. 10, lines 50-68, col. 11, lines 46-66, col. 13, line 25, abstract, col. 1, lines 40, 47, 49, 55-56, col. 10, lines 50-68, col. 11, lines 46-66, col. 13, line 25.	1-3, 5-7, 9-16, 19-20, 24, 26-27 ---- 4, 8, 17-18, 21-23

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means		
*P* document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search  
  
13 AUGUST 1999

Date of mailing of the international search report

19 OCT 1999

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231  
Facsimile No. (703) 305-3230Authorized office  
  
TODD D. WARE  
Telephone No. (703) 308-1234